FTC/SE/88 (07-05):

Approved for use through 7/31/2002. OME 0651-303: U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this ourden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS Applicable. The Information Unit. Constal Plaza Trates, Room 1001, 2021 South Clark Place, Arlington, VA.



(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2002/0193575 A1 Holmes et al.

RECOMBINANT IL4 ANTIBODIES USEFUL IN TREATMENT OF IL4 MEDIATED **DISORDERS**

(75) Inventors: Stephen Dudley Holmes, Surrey (GB); Mitchell Stuart Gross, Wayne, PA (US); Daniel R. Sylvester, Phoenixville, PA (US)

> Correspondence Address: GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 (US)

(73) Assignee: SmithKline Beecham p.l.c.

Appl. No.:

09/879,461-

(22)Filed: Jun. 12, 2001

Related U.S. Application Data

Continuation of application No. 09/426,814, filed on (63)Oct. 22, 1999, now abandoned, which is a continua-

tion of application No. 08/612,929, filed on Apr. 30,

1996, now abandoned, filed as 371 of international

application No. PCT/US94/10308, filed on Sep. 7,

1994, which is a continuation-in-part of application

No. 08/136,783, filed on Oct. 14, 1993, now aban-

doned, which is a continuation of application No.

08/117,366, filed on Sep. 7, 1993, now abandoned.

(43) Pub. Date:

Dec. 19, 2002

Publication Classification

(51) Int. Cl.⁷ C07K 16/46; C07H 21/04; C12P 21/04; C12N 5/06 (52) U.S. Cl. 530/389.1; 536/23.5; 435/69.7; 435/326; 435/320.1

ABSTRACT (57)

Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.